share_log

HC Wainwright & Co. Reiterates Buy on NovoCure, Raises Price Target to $38

Benzinga ·  Dec 2, 2024 10:56  · Ratings

HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $30 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment